Tag: Breyanzi for MCL

Home / Breyanzi for MCL

Categories

Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma

May 2024: The Food and Drug Administration has granted approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory mantle c...
breyanzi-for-mcl

Scan the code